Form 4: Dexcom CEO Kevin Sayer Receives Stock Grant

Dexcom's CEO, Kevin Sayer, reports the acquisition of 85,490 shares of common stock through a grant of restricted stock units.

Summary

• Kevin R. Sayer, CEO and President of Dexcom Inc., reported a transaction on March 8, 2025.
• Sayer acquired 85,490 shares of Dexcom common stock through a grant of restricted stock units.
• These restricted stock units vest in three equal annual installments from the grant date.
• Following the transaction, Sayer beneficially owns 404,527 shares of Dexcom common stock, including unvested restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns management with shareholder interests. There are no indications of negative news or concerns.

Positives

• The grant of restricted stock units to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology and medical device industries, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock grants, are common in publicly traded companies like Dexcom.
• Comparable companies in the medical device sector, such as Medtronic and Abbott, also utilize stock grants as part of their executive compensation strategy.
• The vesting schedule of three years is a standard practice to ensure long-term commitment.

Stakeholder Impact

• The stock grant to the CEO can positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view the stock grant as a positive sign of the company's commitment to its leadership.

Key Dates